Pentetate Zinc Trisodium (Zn-DTPA ) - @ - Chelating agents - Detoxification Agents
Drug Name:
Pentetate Zinc Trisodium (Zn-DTPA ) - @ - Chelating agents - Detoxification Agents
List Of Brands:
Indication Type Description:
Pharmacology/ Pharmacokinetics
Indication:
Radiation Contamination
Adverse Reaction:
Headache,
Light-headedness,
and pelvic pain
Contra-Indications:
Special Precautions-
Exacerbation of asthma- nebulized chelation therapy may be associated with exacerbation
of asthma. Excercise caution when administering pentetate zinc trisodium by inhalation route
Endogenous metal depletion- treatment over several months with pentetate zinc trisodium could
lead to depletion of body stores of endogenous metals eg magnesium, manganese .
Routinely monitor these elements and if appropiate provide mineral or vitamin plus supplements.
Unknown/multiple radiocontaminants- when individual is contaminated with multiple radiocontaminants or unknown additional therapies may be needed eg Prussian Blue,Potassium Iodide
Collection of patient treatment data- to develop long-term response data and information on patient
treatment to the manufacturer , provide detailed information on patient treatment to the manufacturer
Pregnancy- use during pregnancy only if clearly needed. Weigh the risk and benifits of treatment
Lactation- women with known or suspected internal contamination with radiocontaminants
should not breast feed. Take precautions when discarding breast milk.
Children- the safety and efficacy of the nebulized route of administration have not been established
in pediatric population.
Monitoring- closely monitor electrolyte and essential metals during penetrate zinc trisodium
treatment. Mineral or vitamin-plus- mineral supplements may be appropiate
Dosages/ Overdosage Etc:
Indication-
Radiation Contamination
Dosage-
A single initial dose of 1g administered IV
Children and younger than 12 years of age - a single initial dose of 14mg/kg administered IV ,
not to exceed 1g.
Patient Information:
1. In individuals with recent inernal contamination with plutonium , americium or curium, penetate
zinc trisodium treatment increases excretion of radioactivity in the urine. Take appropiate
safety mesasures to minimise contamination of others.
2. When possible use a toilet instead of a urinal , and flush several times after each use.
Completely clean up spilled urine or feces and wash hands throughly. If blood or urine
comes in contact with clothing or linens, wash them separately.
3. Drink plenty of fluids and void frequently
4. If coughing occurs, carefully dispose of any expectorant . Avoid swallowing the expectorant
if possible,
5. Parents and childcare givers should take extra care precaution in handling the urine, feces,
and expectorants from children to avoid any additional exposure to either the caregiver or to
the child.
6. Breast-feeding mothers should take extra precaution in disposal of breast milk.
Pharmacology/ Pharmacokinetics:
Pharmacology-
Penetrate zinc trisodium forms stable chelates with metal ions by exchanging zinc for a metal of
greater binding capacity. The radio actives are excreted by glomerular filtration into the urine.
Pregnancy and lactation:
Pregnancy-
Use during pregnancy only if clearly needed. Weigh the risk and benifits of treatment
Lactation-
Women with known or suspected internal contamination with radioontaminants
should not breast feed. Take precautions whendiscarding breast milk.
Children-
The safety and efficacy of the nebulized route of administration have not been established
in pediatric population.